We will design a biodegradable drug delivery platform for long acting anti-angiogenic therapy in neovascular AMD. The experiments planned will establish anti-angiogenic potency of the modified peptides (Henkin lab) using in vitro assays (Volpert lab) followed by in vivo validation in laser-induced CNV mouse model (Fawzi lab). The most potent peptide will then be linked into a biodegradable polymer (Shea lab). The bioactivity and safety of this polymer will finally be validated in vivo using a subretinal matrigel rat model of prolonged CNV formation (Fawzi lab).
|Effective start/end date||4/1/13 → 9/30/15|
- Macula Society (Ltr. 4/10/13)